Abstract:ABSTRACT SARM1 is an NAD glycohydrolase and TLR adapter with an essential, prodegenerative role in programmed axon death (Wallerian degeneration). It has low basal NADase activity that becomes strongly activated by NAD precursor NMN. Very high levels of NAD oppose this activation, competing for the same allosteric site on SARM1’s regulatory ARM domain. Injury or diseases that deplete axons of NMNAT2, an essential enzyme converting NMN to NAD, cause SARM1 activation. The resulting NAD degradation by SARM1, combined with loss of NAD synthesis by NMNAT2, causes rapid depletion of axonal NAD. This NAD loss is widely assumed to mediate axon death and is consequently a key focus for therapeutic strategies for axonopathies. However, like other NAD(P) glycohydrolases, SARM1 has additional enzyme activities whose contributions, consequences and regulation need to be fully understood. Here, we compare the multiple actions and regulation of recombinant human SARM1 with those of two other NAD(P) glycohydrolases, human CD38 and Aplysia californica ADP ribosyl cyclase. We find that SARM1 has the highest transglycosidation (base exchange) activity of these enzymes at neutral pH and with some bases this dominates NAD(P) hydrolysis and cyclisation. Moreover, like its NADase and NADPase reactions, SARM1-mediated base exchange at neutral pH is activated by increases in the NMN:NAD ratio, which we show for the first time can act in the presence of physiological levels of both metabolites. We establish that SARM1 base exchange is the most likely physiological source of calcium mobilizing agent NaADP, and potentially of other NAD(P) analogues, which could contribute to axon and cell death. We also identify regulatory effects of free pyridine bases, of NADP and of nicotinic acid riboside (NaR) on SARM1 that represent further therapeutic opportunities. These data will help to pinpoint which of the multiple functions of SARM1 is responsible for axon degeneration and how it can be optimally targeted to block axon degeneration in disease.

Dsarm/sarm1 is Required for Activation of an Injury-Induced Axon Death Pathway

The Mrna Decay Factor CAR-1/LSM14 Regulates Axon Regeneration Via Mitochondrial Calcium Dynamics

Sarm1 is not necessary for activation of neuron-intrinsic growth programs yet required for the Schwann cell repair response and peripheral nerve regeneration

SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration

SARM1 is responsible for calpain-dependent dendrite degeneration in mouse hippocampal neurons

An Ionic Sensor acts in Parallel to dSarm to Promote Neurodegeneration

Structural and Mechanistic Regulation of the Pro-degenerative NAD Hydrolase SARM1

SARM1 Activation Promotes Axonal Degeneration Via a Two-Step Liquid-to-Solid Phase Transition

Gene therapy targeting SARM1 blocks pathological axon degeneration in mice

SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration

The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products

Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves

Sarm1-Dependent Metabolic Reprogramming of Schwann Cells Following Nerve Injury

Programmed axon death executor SARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated by physiological levels of NMN, NAD, NADP and other metabolites

Deubiquitination of SARM1 by USP13 Regulates SARM1 Activation and Axon Degeneration

Gap Junction Intercellular Communications Regulates Activation of SARM1 and Protects Against Axonal Degeneration

The NAD+-mediated Self-Inhibition Mechanism of Pro-Neurodegenerative SARM1.

Mitophagy Eliminates the Accumulation of SARM1 on the Mitochondria, Alleviating Programmed Axon Death in Acrylamide Neuropathy

Macrophage Depletion Blocks Congenital SARM1-dependent Neuropathy

Pathological Axonal Death through a MAPK Cascade that Triggers a Local Energy Deficit

Sarm1/Myd88-5 Regulates Neuronal Intrinsic Immune Response to Traumatic Axonal Injuries.